Genomic mapping of metastatic organotropism in lung adenocarcinoma
Lengel H, Mastrogiacomo B, Connolly J, Tan K, Liu Y, Fick C, Dunne E, He D, Lankadasari M, Satravada B, Sun Y, Kundra R, Fong C, Smith S, Riely G, Rudin C, Gomez D, Solit D, Berger M, Li B, Mayo M, Matei I, Lyden D, Adusumilli P, Schultz N, Sanchez-Vega F, Jones D. Genomic mapping of metastatic organotropism in lung adenocarcinoma. Cancer Cell 2023, 41: 970-985.e3. PMID: 37084736, PMCID: PMC10391526, DOI: 10.1016/j.ccell.2023.03.018.Peer-Reviewed Original ResearchConceptsActionable alterationsPrimary tumorMetastasis-free survivalHigh mutational burdenAPOBEC mutational signatureSolid histological subtypeMetastatic burdenClinicopathological featuresHistological subtypesLung adenocarcinomaMutational burdenLiver lesionsInactivation of TP53Tumor genomicsMetastasisMetastatic organotropismUnknown significanceGenomic alterationsOrganotropismMutational signaturesTumorsNumber alterationsAlterationsBurdenChromosomal instability